Characterization of a novel HBB:c.194dup variant of the β-globin gene combined with six alpha genes

Jungao Huang1, Le Ding1, Junkun Chen1, Shiping Chen2, Peirun Tian2, Jun Xie3, Xiaoyan Huang2 and Xiaoqin Xin4

Abstract
β-thalassemia (β-thal) is one of the most prevalent inherited blood disorders in Ganzhou, south China. Next-generation sequencing was used to screen for thalassemia carriers in the general population. During the screening, we identified a novel β-thal variant in a 46-year-old Chinese man, which was validated by Sanger sequencing. Based on the patient’s clinical data, this novel mutation was classified as severe β0. However, the patient was mildly anemic (hemoglobin, 89 g/L), which was inconsistent with typical β0 carrier characteristics. On further evaluation, quantitative PCR indicated the presence of six α genes, while molecular analysis and pedigree analysis revealed the coexistence of αααααα3.7 and αααααα4.2. Therefore, we report a novel β-thal variant combined with six α genes. We describe the patient’s clinical phenotype and the process of molecular diagnosis. This case extends the spectrum of thalassemia variants.

Keywords
Novel variant, next-generation sequencing, alpha triplication, β globin gene, β-thalassemia, anemia

Date received: 26 November 2021; accepted: 14 April 2022

Introduction
The β-globin protein (HBB) is synthesized from the β-globin gene (HBB) located on chromosome 11. β-globin in combination with α-globin forms the most common adult hemoglobin (HbA).1 Abnormal HBB variants influence every stage of gene expression, affecting the stability and
synthesis of the β-globin chain, resulting in inherited forms of β-thalassemia (β-thal). More than 300 variants of HBB resulting in β-thal have been described globally, according to the human hemoglobin (Hb) variant (HbVar) database.² HBB variants alter the synthesis of HBB either partially (β⁺) or completely (β⁰), with varying effects on clinical severity.³

β-thal carriers are clinically characterized by a low mean corpuscular volume (MCV) and mean corpuscular Hb (MCH), elevated Hb A2 levels,⁴ and normal Hb levels. Common β-thal variants are identified through hematological indices; 17 HBB mutations have been detected in the Chinese population through reverse dot-blot hybridization (RDB).⁵ However, rare or novel β-thal variants could be missed when using these common methods. In a population with a high prevalence of thalassemia, couples are at risk of having children with severe β-thal, including those with rare thalassemia. Therefore, gap-PCR, multiplex ligation-dependent probe amplification, and Sanger sequencing are used to identify potential carriers of rare β-thal variants.⁶,⁷

The frequency of thalassemia alleles in Ganzhou, southern China, is 9.49% which is relatively high.⁸ The Thalassemia Prevention Program plays a vital role in regions where the thalassemia prevalence is high. Thalassemia screening strategies and methods vary among regions. Next-generation sequencing (NGS) is a competitive method that could improve screening for thalassemia carriers, and provide an integrated assessment strategies in populations with a high thalassemia prevalence.⁹

To accurately assess the prevalence of thalassemia in the population and avoid missing rare thalassemia variants, NGS was applied for the genetic screening of thalassemia in Ganzhou.

During the screening, a novel heterozygous variant was identified in a 46-year-old Chinese man. This novel frameshift variant in the β-globin gene [NM_00518.4 (HBB): c.194dup and: p.(Lys66Glnfs*8)] was validated through different methods. This β-thal mutation correlated with the abnormal hematological parameters of the patient. We herein report the variant for the first time.

**Case presentation**

A 46-year-old Chinese man (the patient) and his wife approached our genetic laboratory for thalassemia carrier status screening before their wedding. As shown in Figure 1, this was the patient’s second wedding. Hematological screening of the

![Pedigree chart](image1.png)  
![Blood cell morphology](image2.png)

**Figure 1.** Pedigree chart and blood cell morphology. (a) Black arrow indicates the patient and (b) Black arrow indicates abnormal red blood cells from the patient seen under optical microscopy.
patient revealed changes in his erythrocyte morphology, low hematological indices, and high levels of hemoglobin (Hb)A2. The patient’s wife had normal hematological indices and HbA2 levels. Hematological data were not available for some family members, including the patient’s 80-year-old mother; his father was deceased. DNA extracted from saliva samples of the patient’s mother showed her genotype to be $\text{aaa}_{\text{anti}3.7}/\text{aaa}$, $\beta^N/\beta^N$. The patient’s ex-wife and 16-year-old daughter refused to participate in the hematological investigation or to provide DNA samples. The patient’s sister and brother agreed to additional family investigation. Study participants gave their informed written consent to provide all hematological and clinical data, and denied any history of blood transfusion. Study approval by an ethics committee or institutional review board was waived because of the voluntary nature of testing.

Full-length HBB, HBA1, and HBA2 sequences were amplified from the DNA of study participants by PCR as previously described by He et al.,10 and the amplicons were confirmed to contain all exons and introns; this ensured that as many variants as possible could be detected in the HbVar database. Sequencing libraries were constructed using the Illumina HiSeq Sequencing Library Preparation Protocol. These libraries underwent paired-end sequencing for 100 base pairs using an Illumina HiSeq 2000 sequencing system, and bioinformatic analysis was performed as described previously.10 The direct sequencing of HBB was performed to validate the novel variant using forward primer: 5'-AGAAACTGGGCGATGTGGA GA-3’ and reverse primer: 5'-ACGATCCTGAGACTTCCACA-3’.

Family members were also tested for the presence of α- or β-thalassemia-associated common deletions using HBA1 and HBA2 quantitative (q)PCR; cycling conditions and primer details have been described previously.11 Bands corresponding to $\text{aaa}_{\text{anti}4.2}$ and $\text{aaa}_{\text{anti}3.7}$ were obtained using 4% agarose gel electrophoresis following gap-PCR; PCR and primer details have been described previously.12 Hematological findings of the patient and his wife, sister, and brother are shown in Table 1. The patient’s hematological parameters included a low MCV and MCH, and elevated HbA2 levels. Direct sequencing indicated a HBB frameshift variant (Figure 2); this was a novel variant, HBB:c.194dup (Figure 2). A single G was duplicated at position 194, which resulted in a premature stop codon at codon 72. Prediction tools PolyPhen-2

Table 1. Hematological and molecular data of the family carrying the HBB: c.194dup mutation.

| Parameter | Patient | Wife | Sister | Brother | Normal |
|-----------|---------|------|--------|---------|--------|
| Sex-age (years) | M-46 | F-39 | F-43 | M-55 | – |
| RBC ($10^{12}$/L) | 4.02 | 4.38 | 4.67 | 4.59 | 3.5–5.0 |
| Hb (g/L) | 89 | 121 | 127 | 107 | 110–160 |
| MCV (fL) | 67.6 | 80.6 | 84.1 | 77.5 | 80.0–100.0 |
| MCH (pg) | 22.1 | 27.6 | 28.1 | 22.7 | 27.0–24.0 |
| HbA (%) | 94.8 | 96.9 | 97.3 | 96.8 | ≥94.5 |
| HbA2 (%) | 5.0 | 2.7 | 2.6 | 2.7 | 2.6–3.5 |
| Hbf (%) | 0.2 | 0.4 | 0.1 | 0.5 | <2 |
| α-genotype | $\text{aaa}_{\text{anti}4.2}/\text{aaa}_{\text{anti}3.7}$ | $\text{aaa}/\text{aaa}$ | $\text{aaa}/\text{aaa}$ | $\text{aaa}_{\text{anti}4.2}/\text{aaa}$ | $\text{aaa}/\text{aaa}$ |
| β-genotype | $\beta^N/\beta^N$ | $\beta^N/\beta^N$ | $\beta^N/\beta^N$ | $\beta^N/\beta^N$ | $\beta^N/\beta^N$ |

RBC: red blood cell count; Hb: hemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular Hb; –: NA; HbA: adult hemoglobin; Hbf: fetal hemoglobin.
Figure 2. Sanger sequencing of the HBB: c.194 dup mutation. Forward and reverse sequencing data show the codon 64 duplication in the heterozygous state. Numerous ambiguities are seen as overlapping peaks.

Figure 3. Copy numbers of HBA1 (2) and HBA2 (4) as determined by qPCR. N, negative, $xx/xx$; P, positive, SEA/$xx$; qPCR, quantitative PCR.
and SIFT (http://sift.jcvi.org/index.php) were used to predict the impact of the novel variant. According to American College of Medical Genetics and Genomics guidelines, strong evidence of pathogenicity (PVS1, PM2, and PP3) was obtained. The patient did not carry any of the common α-thalassemia variants, as indicated by gap-PCR and NGS. However, his Hb level was low and qPCR showed the amounts of HBA2 and HBA1 to be 4 and 2, respectively (Figure 3). PCR indicated the presence of both Hbaaanti4.2 and Hbaaanti3.7 (Figure 4), so the patient’s thalassemia genotype was described as Hbaaanti4.2/ Hbaaanti3.7, βCD64M/βN. The patient’s wife was shown to be αα/αα, βN/βN. The reporting of this study conforms to CARE guidelines.

**Discussion and conclusions**

Many variants responsible for β-thal have been identified and extensively characterized. Most result from single base substitutions, deletions, or insertions in coding regions or at exon–intron classical junction regions that affect almost every stage of HBB expression, including transcription, splicing, polyadenylation, or translation of mRNA.14

In this study, a novel variant [HBB: c.194dup] was characterized in the heterozygous state. Taking the hematological indices into account, it was expected to be classified as the β⁰ type. However, the Hb level of the patient was low. Subsequently, qPCR indicated the presence of both Hbaaanti4.2 and Hbaaanti3.7. These triplicated alleles resulted from an unequal crossover between the homologous X-, Y-, and Z-boxes.

![Figure 4. Agarose gel electrophoresis of PCR amplicons. Lanes 1 and 2, samples from patient’s mother positive for and negative for Hbaaanti3.7 and Hbaaanti4.2; lane 3, marker; lanes 4 and 6, negative controls for Hbaaanti3.7 and Hbaaanti4.2, respectively; lanes 5 and 7, positive controls for Hbaaanti3.7 and Hbaaanti4.2, respectively; lanes 8 and 9, samples from patient positive for Hbaaanti3.7 and Hbaaanti4.2; lanes 10 and 11, samples from patient’s sister negative for Hbaaanti3.7 and Hbaaanti4.2; lanes 12 and 13, samples from patient’s brother negative for Hbaaanti3.7 and positive for Hbaaanti4.2.](image-url)
segments of the α-globin gene cluster during meiosis. Further pedigree analysis ruled out α<sup>anti4.2</sup>α<sup>anti3.7</sup>α/αα as an alternative possibility for the α thalassemia genotype, which could have resulted from an unequal crossover between ααα<sup>anti3.7</sup> and normal αα.

The patient’s α-thalassemia genotype of ααα<sup>anti4.2</sup>/ααα<sup>anti3.7</sup> is in agreement with those of his brother and mother. These alpha triplications result in a higher α chain expression in carriers than in healthy individuals. The α chain expression hierarchy is ααα<sup>anti4.2</sup> > ααα<sup>anti3.7</sup> > HK αα = αα.<sup>11</sup> Therefore, the coinheritance of triplicated alleles in the patient aggravated the clinical features of the novel heterozygous β<sup>0</sup>-thal, because of the uneven ratio of α and β chains. This could explain his low Hb levels. However, the Hb level in this patient was much higher than that seen in a previous patient (Hb, 56 g/L) diagnosed with ααα<sup>anti4.2</sup>/ααα<sup>anti3.7</sup> and β<sup>41–42</sup>/β<sup>N</sup>.<sup>11</sup> Additionally, five triplicated α-globin cases coinherited with heterozygote β-thal presented with various clinical manifestations of anemia.<sup>15</sup>

In summary, novel thalassemia variants could be identified in populations where thalassemia is prevalent. Updating the spectrum of variants will enable greater precision in prenatal diagnosis and genetic counselling. Moreover, including new β-thal variants identified locally will improve screening for β-thal mutations using the traditional RDB hybridization method. This will overcome the limitations of regular screening for only the 17 most common β-thal mutations. Future studies should focus on developing a time- and cost-efficient method of comprehensive DNA screening, using tools such as NGS.

**Acknowledgements**
We would like to thank the participant’s family for participating in this study.

**Declaration of conflicting interest**
The authors have no conflict of interest to report.

**Funding**
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding was provided by The Research Project of the Health Department of Jiangxi Province and The Research Project of the Health Department of Ganzhou (grant numbers: 202212360 and 2022-2-218, respectively).

**ORCID iD**
Xiaoqin Xin https://orcid.org/0000-0002-6942-5731

**References**
1. Aldakeel SA, Ghanem NZ, Al-Amodi AM, et al. Identification of seven novel variants in the β-globin gene in transfusion-dependent and normal patients. *Arch Med Sci* 2020; 16: 453–459.
2. Chen JK, Xin XQ and Huang JG. A novel β-thalassemia mutation in a Chinese family: IVS-II-203-205 (TCT > CC) (HBB: c.315 + 203TCT > CC). *Hemoglobin* 2018; 42: 159–160.
3. Hajihoseini S, Motovali-Bashi M, Honardoost M, et al. Tetra-primer ARMS PCR optimization for detection of IVS-II-I (G-A) and FSC 8/9 InsG mutations in β-thalassemia major patients in Isfahan population. *Iran J Public Health* 2015; 44: 380–387.
4. Forouzesh Pour F, Karimi K, Ghaderi Z, et al. Heterozygosity for the novel HBA2: c.*91_92delTA polyadenylation site variant on the α2-globin gene expanding the genetic spectrum of α-thalassemia in Iran. *Hemoglobin* 2020; 44: 423–426.
5. Xu L, Chen M, Huang H, et al. Identification of a novel pre-terminating mutation in human HBB gene as a cause of $\beta^0$-thalassemia phenotype. *Int J Clin Exp Pathol* 2019; 12: 3070–3076.

6. He S, Wei Y, Lin L, et al. The prevalence and molecular characterization of $(\delta\beta)$-thalassemia and hereditary persistence of fetal hemoglobin in the Chinese Zhuang population. *J Clin Lab Anal* 2018; 32: e22304.

7. Zhang J, Yang Y, Li P, et al. Analysis of deletional hereditary persistence of fetal hemoglobin/$(\delta\beta)$-thalassemia and $\delta$-globin gene mutations in Southernwestern China. *Mol Genet Genomic Med* 2019; 7: e706.

8. Lin M, Zhong TY, Chen YG, et al. Molecular epidemiological characterization and health burden of thalassemia in Jiangxi Province, P. R. China. *PLoS One* 2014; 9: e101505.

9. Zhang H, Li C, Li J, et al. Next-generation sequencing improves molecular epidemiological characterization of thalassemia in Chenzhou region, P.R. China. *J Clin Lab Anal* 2019; 33: e22845.

10. He J, Song W, Yang J, et al. Next-generation sequencing improves thalassemia carrier screening among premarital adults in a high prevalence population: the Dai nationality, China. *Genet Med* 2017; 19: 1022–1031.

11. Long J and Liu E. The carriage rates of $\alpha^0\alpha^0\alpha^0$, $\alpha^0\alpha^0\alpha^+$, and HK$\alpha^+$ in the population of Guangxi, China measured using a rapid detection qPCR system to determine CNV in the $\alpha$-globin gene cluster. *Gene* 2020; 19: 1–13.

12. Wang W, Ma ES, Chan AY, et al. Single-tube multiplex-PCR screen for anti-3.7 and anti-4.2 alpha-globin gene triplications. *Clin Chem* 2003; 49: 1679–1682.

13. Gagnier JJ, Kienle G, Altman DG, et al; CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. *Headache* 2013; 53: 1541–1547.

14. Jiang F, Huang LY, Chen GL, et al. A novel frameshift mutation at codons 138/139 (HBB: c.417_418insT) on the $\beta$-globin gene leads to $\beta$-thalassemia. *Hemoglobin* 2017; 41: 59–60.

15. Luo X, Zhang XM, Wu LS, et al. Prevalence and clinical phenotype of the triplicated $\alpha$-globin genes and its ethnic and geographical distribution in Guizhou of China. *BMC Med Genomics* 2021; 14: 97.